Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Total Non-Current Liabilities (2024 - 2026)

Maze Therapeutics' Total Non-Current Liabilities history spans 3 years, with the latest figure at $77.6 million for Q1 2026.

  • On a quarterly basis, Total Non-Current Liabilities rose 95.19% to $77.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $77.6 million, a 95.19% increase, with the full-year FY2025 number at $41.1 million, down 3.75% from a year prior.
  • Total Non-Current Liabilities hit $77.6 million in Q1 2026 for Maze Therapeutics, up from $41.1 million in the prior quarter.
  • Over the last five years, Total Non-Current Liabilities for MAZE hit a ceiling of $77.6 million in Q1 2026 and a floor of $39.8 million in Q1 2025.
  • Historically, Total Non-Current Liabilities has averaged $47.1 million across 3 years, with a median of $41.3 million in 2025.
  • Biggest five-year swings in Total Non-Current Liabilities: decreased 3.75% in 2025 and later skyrocketed 95.19% in 2026.
  • Tracing MAZE's Total Non-Current Liabilities over 3 years: stood at $42.7 million in 2024, then dropped by 3.75% to $41.1 million in 2025, then surged by 89.01% to $77.6 million in 2026.
  • Business Quant data shows Total Non-Current Liabilities for MAZE at $77.6 million in Q1 2026, $41.1 million in Q4 2025, and $41.5 million in Q3 2025.